Osteoporosis is a condition of low bone mass which predisposes to fractures. This silently progressive metabolic bone disease is widely prevalent in India in both sexes and occurs at younger age than in western population. Rapid bone loss occurs in postmenopausal women due to hormonal factors. Indians have low bone density compared to Caucasians. High prevalence of vitamin D deficiency is a major factor for poor bone health in India. The bone health of population can be improved by encouraging children to drink milk and take enough exercise. Results of randomised trials have revolutionised treatments and several effective therapeutic drugs are available. Despite new treatments many patients with fractures still do not receive appropriate management. Early detection and management of this condition can avoid the risk of fractures and associated morbidity and mortality.
Introduction
Osteoporosis is one of the most common diseases affecting 1 in 3 women and 1 in 12 men by the end of their lives. Worldwide approximately 200 million women suffer from osteoporosis. By the age of 50 the lifetime risk of fracture related to osteoporosis is nearly 40%. [1] Osteoporosis is a silent disease reflected many times by low bone density until a fracture occurs. It has been called as 'silent epidemic as it is a growing problem and many patients are asymptomatic. With increasing longevity of Indian population, as in the West, osteoporotic fractures are a major cause of mortality and morbidity in the elderly. The 2001 census showed approximately 163 million Indians are above the age of 50 years. [2] Of these 20% women and 10-15% men would be osteoporotic. The total estimated numbers of osteoporosis patients in India are estimated around 26 million and the numbers are projected to increase to 36 million by 2013. [3] Osteoporotic fractures are common in India and occur in both sexes based on published data from 1393 patients with hip fractures from 3 large hospitals in Delhi. [4] The average age of fracture is 49 years in men and 57 years in women. [5] The word osteoporosis is derived from the Greek word osteon for bone and poros for porosity indicating that the bone becomes more porous. Osteoporosis is defined as a systemic skeletal disease characterised by low bone mass and disruption of bone architecture resulting in reduced bone strength and increased risk of fracture. [6] 
Pathophysiology
The main components of bone are cells, organic matrix and minerals. The osteoblast cell (fibroblast) synthesizes bone collagen and other components of matrix. Osteoclasts (of haemopoetic origin) resorb bone. The skeleton is continuously being removed and replaced by osteoclastic and osteoblastic activity and about 10% of adult skeleton is remodelled every year. The adult human skeleton contains about 20% trabecular and 80% cortical bone. The bone mass achieves peak around the age of 30 years after which osteoclastic activity exceeds that of osteoblasts resulting in bone loss. This loss exceeds in trabecular bone than in cortical bone. This loss is greater in women especially after menopause. In 3 to 6 years following menopause, bone loss occurs at rate of 3 to 55 per year and is mainly due to estrogen deficiency. Osteoporotic fractures tend to occur in sites of mainly trabecular bone such as femur, spine and wrist. In older population diminished calcium absorption causes further calcium loss from bone due to effect of parathyroid hormone. Moreover certain pathological conditions increase risk of osteoporosis. 
Types of Osteoporosis

Clinical Presentation
The commonest presentation of osteoporosis is a fracture. The most common sites are hip, vertebrae and forearm. Fractures of forearm and spine are most prevalent in women up to the age of 70 years after which hip fractures become more significant. 
Hormone Replacement Therapy
Apart from relieving menopausal symptoms HRT is useful for prevention and treatment of osteoporosis. It is available in oral, transdermal and implant forms and is well tolerated. HRT halves the risk of osteoporotic fractures if given for 5 to 10 years starting at menopause. [23] To achieve maximum benefit HRT is taken for 10 years. It can also be used in older women. Estrogen alone can be given to those patients with hysterectomy but for the remainder a combined preparation is indicated to protect the uterus. The patients should be informed about increased risk of breast and uterine cancer and thromboembolism.
Vaginal bleeding can be troublesome side effect. Recent evidence indicates that HRT is not protective against coronary heart disease as previously believed; furthermore HRT increases risk of stroke, breast cancer and thromboembolism. Now the consensus is that despite protection against osteoporosis, the risk benefit profile is unfavourable for majority of postmenopausal women.
Teriparatide
Parathyroid hormone (1-34 teriparatide) administered intermittently has dramatic effects on skeleton. In a randomised trial, Teriparatide 20 µg or 40 µg administered daily by subcutaneous injection showed significant increase in bone density and reduction of upto 65-70% in vertebral fractures and 54% of non-vertebral fractures. [24] However the treatment is limited to 18 months, is more expensive hence reserved for use in patients intolerant or unresponsive to other agents. PTH 1-84 has also been shown to reduce fractures in postmenopausal women given New Drug Treatments: Several new approaches to osteoporosis therapy are emerging.
Conclusion
The diagnosis and management of osteoporosis has revolutionised in the last decade. Large randomised trials have added new drugs for the management of this silent condition. With growing elderly population the burden of osteoporosis and resulting fractures is likely to increase in the future. Despite significant advances many patients do not receive adequate treatments. Health professionals have an important role in prevention and management of osteoporosis.
